EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists

This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Stephen V., Elkins, Ivy B., Feldman, Jill, Goldberg, Sarah B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673799/
https://www.ncbi.nlm.nih.gov/pubmed/37750968
http://dx.doi.org/10.1007/s40487-023-00242-7
_version_ 1785140696055808000
author Liu, Stephen V.
Elkins, Ivy B.
Feldman, Jill
Goldberg, Sarah B.
author_facet Liu, Stephen V.
Elkins, Ivy B.
Feldman, Jill
Goldberg, Sarah B.
author_sort Liu, Stephen V.
collection PubMed
description This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small cell lung cancer. The treatment landscape for EGFR-mutated non-small cell lung cancer is evolving, and biomarker testing has become central to determining the best therapies for individual patients. The panel discusses what biomarkers are, the processes involved in obtaining biomarker testing, how biomarker information is used, and the importance of waiting for biomarker results prior to determining treatment. The panel also discusses patient perspectives on biopsy and biomarker testing and how HCPs can best help guide new patients through this process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-023-00242-7.
format Online
Article
Text
id pubmed-10673799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106737992023-09-26 EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists Liu, Stephen V. Elkins, Ivy B. Feldman, Jill Goldberg, Sarah B. Oncol Ther Commentary This podcast, for healthcare professionals (HCPs), patients, and patient advocates, is a discussion among a panel of two patients (and co-founders of the patient advocacy group EGFR Resisters, https://egfrcancer.org/) and two oncologists. The objective of the podcast is to explain the importance of biomarker testing for patients with EGFR-mutated non-small cell lung cancer. The treatment landscape for EGFR-mutated non-small cell lung cancer is evolving, and biomarker testing has become central to determining the best therapies for individual patients. The panel discusses what biomarkers are, the processes involved in obtaining biomarker testing, how biomarker information is used, and the importance of waiting for biomarker results prior to determining treatment. The panel also discusses patient perspectives on biopsy and biomarker testing and how HCPs can best help guide new patients through this process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40487-023-00242-7. Springer Healthcare 2023-09-26 /pmc/articles/PMC10673799/ /pubmed/37750968 http://dx.doi.org/10.1007/s40487-023-00242-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Liu, Stephen V.
Elkins, Ivy B.
Feldman, Jill
Goldberg, Sarah B.
EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title_full EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title_fullStr EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title_full_unstemmed EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title_short EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
title_sort egfr mutations are not all the same: the importance of biomarker testing in non-small cell lung cancer (nsclc)—a podcast discussion between patients and oncologists
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673799/
https://www.ncbi.nlm.nih.gov/pubmed/37750968
http://dx.doi.org/10.1007/s40487-023-00242-7
work_keys_str_mv AT liustephenv egfrmutationsarenotallthesametheimportanceofbiomarkertestinginnonsmallcelllungcancernsclcapodcastdiscussionbetweenpatientsandoncologists
AT elkinsivyb egfrmutationsarenotallthesametheimportanceofbiomarkertestinginnonsmallcelllungcancernsclcapodcastdiscussionbetweenpatientsandoncologists
AT feldmanjill egfrmutationsarenotallthesametheimportanceofbiomarkertestinginnonsmallcelllungcancernsclcapodcastdiscussionbetweenpatientsandoncologists
AT goldbergsarahb egfrmutationsarenotallthesametheimportanceofbiomarkertestinginnonsmallcelllungcancernsclcapodcastdiscussionbetweenpatientsandoncologists

Ejemplares similares